Skip to main content
. 2021 Jun 3;13(6):833. doi: 10.3390/pharmaceutics13060833

Figure 5.

Figure 5

Schematic representation of a model used to characterize the aztreonam-avibactam killing effect on drug susceptible (P1) and less susceptible (P2) bacteria. Adapted from [47]; Published by the American Society for Clinical Pharmacology and Therapeutics, 2019.